Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

Q1_2022_100x80

Quarterly Statement First Quarter 2022

DOWNLOAD TOOL

Investment Case

Event Highlights

June 29, 2022

Enhancing Transparency: Bayer’s UN Global Compact adherence Webinar

May 10, 2022

Investor Conference Call

Q1 2022 Results

Virtual Event: Annual Stockholders’ Meeting 2022

April 1, 2022

Bayer Breakthrough Innovation Forum

March 1, 2022

Investor Conference Call

FY/Q4 2021 Results

News from Bayer

June 08, 2022

Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation

May 23, 2022

Not intended for U.S. and UK Media - Late-breaking data from exploratory post hoc analysis of prespecified pooled analysis FIDELITY presented at Heart Failure 2022 of the Heart Failure Association of the European Society of Cardiology (ESC)

New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes

May 19, 2022

Not intended for U.S. and UK Media

Verquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction

NEWS OVERVIEW